CEGIR study sites are conducting this study to learn more about Eosinophilic Gastrointestinal Diseases (EGIDs). As part of that goal, one area of study will compare how well a patient feels – their symptoms – with what the tissue samples look like under a microscope. This annual questionnaire will aim to answer a series of questions including the following: - What if the tissue looks good, but you are still experiencing symptoms? - What if the symptoms have subsided, but the eosinophil counts haven’t changed? The participants also have the option to provide their biopsy/blood samples during their standard of care procedures.
Industry Sponsored Research Studies
*CROSSING Study – Sponsor AstraZeneca - Evaluating the safety and efficacy of Tezepelumab for the treatment of Eosinophilic Esophagitis (EoE) in patients who are 12 years of age or older.
The aim of this Phase III study is to investigate the use of tezepelumab as a treatment for patients with EoE. This study will evaluate the efficacy and safety of tezepelumab 210 mg every 4 weeks and tezepelumab 420 mg administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in EoE participants for 52 weeks followed by an active treatment extension period of 24 weeks.
*Immune-Mediated Disorders Registry - Sponsor AstraZeneca– Enrolling EOE patients for a one-time collection of 6ml whole blood for whole genome sequencing to understand the genetic variants contributing to EoE predisposition, progression and outcomes.
Enrolling Soon
*EDESIA – Dupilumab Registry – Sponsor Regeneron - registry of EoE patients treated with Dupixent, according to the U.S. prescribing information, who will be followed for up to 3 years after treatment initiation.
For any questions about our research studies, please contact our EGID research coordinator, Amanda Vega (axvega6@texaschildrens.org)
